CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice.


Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
04 2023
Historique:
received: 06 10 2022
revised: 16 02 2023
accepted: 26 02 2023
pubmed: 7 3 2023
medline: 23 3 2023
entrez: 6 3 2023
Statut: ppublish

Résumé

The APOE4 allele increases the risk for Alzheimer's disease (AD) in a dose-dependent manner and is also associated with cognitive decline in non-demented elderly controls. In mice with targeted gene replacement (TR) of murine APOE with human APOE3 or APOE4, the latter show reduced neuronal dendritic complexity and impaired learning. APOE4 TR mice also show reduced gamma oscillation power, a neuronal population activity which is important to learning and memory. Published work has shown that brain extracellular matrix (ECM) can reduce neuroplasticity as well as gamma power, while attenuation of ECM can instead enhance this endpoint. In the present study we examine human cerebrospinal fluid (CSF) samples from APOE3 and APOE4 individuals and brain lysates from APOE3 and APOE4 TR mice for levels of ECM effectors that can increase matrix deposition and restrict neuroplasticity. We find that CCL5, a molecule linked to ECM deposition in liver and kidney, is increased in CSF samples from APOE4 individuals. Levels of tissue inhibitor of metalloproteinases (TIMPs), which inhibit the activity of ECM-degrading enzymes, are also increased in APOE4 CSF as well as astrocyte supernatants brain lysates from APOE4 TR mice. Importantly, as compared to APOE4/wild-type heterozygotes, APOE4/CCR5 knockout heterozygotes show reduced TIMP levels and enhanced EEG gamma power. The latter also show improved learning and memory, suggesting that the CCR5/CCL5 axis could represent a therapeutic target for APOE4 individuals.

Identifiants

pubmed: 36878326
pii: S0969-9961(23)00071-2
doi: 10.1016/j.nbd.2023.106057
pmc: PMC10291850
mid: NIHMS1906911
pii:
doi:

Substances chimiques

Apolipoprotein E4 0
Apolipoprotein E3 0
Apolipoproteins E 0
CCR5 protein, human 0
Receptors, CCR5 0

Banques de données

ClinicalTrials.gov
['NCT01504854']

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

106057

Subventions

Organisme : NIA NIH HHS
ID : R01 AG077002
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS100704
Pays : United States
Organisme : NINDS NIH HHS
ID : T32 NS121780
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG010483
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest There are no competing financial interests for any of the authors in relation to the work described.

Références

Lancet. 1993 Sep 18;342(8873):697-9
pubmed: 8103819
Lancet Neurol. 2007 Jun;6(6):494-500
pubmed: 17509484
Biol Psychiatry. 2007 Aug 15;62(4):359-62
pubmed: 17210139
Neurobiol Dis. 1996;3(3):229-45
pubmed: 8980023
Neuron. 2009 Aug 13;63(3):287-303
pubmed: 19679070
J Cell Biol. 2007 Aug 13;178(4):687-700
pubmed: 17682049
Biochim Biophys Acta Gen Subj. 2017 Oct;1861(10):2420-2434
pubmed: 28625420
J Cereb Blood Flow Metab. 2016 Jan;36(1):216-27
pubmed: 25757756
J Neuroinflammation. 2011 Jun 01;8:61
pubmed: 21631912
Biomolecules. 2021 Oct 11;11(10):
pubmed: 34680129
Neurobiol Dis. 2005 Mar;18(2):390-8
pubmed: 15686968
Cell. 2019 Feb 21;176(5):1143-1157.e13
pubmed: 30794775
Nature. 2016 Dec 7;540(7632):230-235
pubmed: 27929004
Nature. 2020 May;581(7806):71-76
pubmed: 32376954
J Neurol Sci. 2001 Aug 15;189(1-2):93-8
pubmed: 11535238
Neurology. 1997 Apr;48(4):985-9
pubmed: 9109888
Elife. 2021 Jun 08;10:
pubmed: 34099103
J Biol Chem. 1997 Jul 18;272(29):17972-80
pubmed: 9218423
J Biol Chem. 1995 Nov 10;270(45):27206-12
pubmed: 7592978
J Neurosci. 2008 Nov 5;28(45):11445-53
pubmed: 18987181
Neurobiol Dis. 2005 Feb;18(1):75-82
pubmed: 15649697
Elife. 2017 Sep 06;6:
pubmed: 28875930
Nat Neurosci. 2021 Oct;24(10):1475-1487
pubmed: 34413515
Cell. 2022 Jun 23;185(13):2213-2233.e25
pubmed: 35750033
J Neurosci. 2020 May 27;40(22):4418-4431
pubmed: 32269106
J Neurosci. 2017 Feb 1;37(5):1269-1283
pubmed: 28039374
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19520-5
pubmed: 19047646
Nature. 2022 Jun;606(7912):146-152
pubmed: 35614219
PLoS One. 2013 Jul 02;8(7):e69136
pubmed: 23844251
Neuropathol Appl Neurobiol. 2017 Feb;43(2):167-182
pubmed: 26544797
J Neurosci. 2007 Oct 3;27(40):10895-905
pubmed: 17913923
Int J Cancer. 2009 Aug 15;125(4):844-50
pubmed: 19431211
Front Cell Neurosci. 2015 Aug 11;9:305
pubmed: 26321910
Redox Biol. 2021 Oct;46:102067
pubmed: 34315111
Alzheimers Dement. 2007 Jul;3(3):186-91
pubmed: 19595937
Neural Plast. 2018 Feb 4;2018:5735789
pubmed: 29531525
Front Syst Neurosci. 2021 Dec 13;15:782399
pubmed: 34966263
Hippocampus. 2018 Jan;28(1):42-52
pubmed: 28921856
Ann Neurol. 1999 Sep;46(3):391-8
pubmed: 10482270
Science. 1993 Aug 13;261(5123):921-3
pubmed: 8346443
Neuroscience. 2010 Mar 17;166(2):508-21
pubmed: 20045450
Trends Neurosci. 2022 Jun;45(6):483-498
pubmed: 35430102
Stroke. 2004 Jun;35(6):e159-62
pubmed: 15105518
Mol Neurodegener. 2009 May 27;4:21
pubmed: 19725929
Aging Dis. 2021 Feb 1;12(1):72-92
pubmed: 33532129
Front Integr Neurosci. 2022 May 25;16:896400
pubmed: 35694184
Nat Med. 2019 Mar;25(3):496-506
pubmed: 30692699
J Biol Chem. 2000 Dec 8;275(49):38885-90
pubmed: 10986281
Sci Rep. 2016 Oct 20;6:35497
pubmed: 27762280
Neuron. 1993 Oct;11(4):575-80
pubmed: 8398148
Cell Rep. 2021 Jul 6;36(1):109313
pubmed: 34233180
J Neurosci. 2009 Dec 2;29(48):15317-22
pubmed: 19955384
J Vis Exp. 2012 Feb 26;(60):
pubmed: 22395674
J Neurochem. 2013 Jan;124(1):109-22
pubmed: 23113835
Science. 2001 Nov 30;294(5548):1945-8
pubmed: 11729324
Neuroreport. 2004 Dec 3;15(17):2655-8
pubmed: 15570172
JAMA. 1995 Mar 22-29;273(12):942-7
pubmed: 7884953
Exp Neurol. 2015 Mar;265:48-58
pubmed: 25483398
Glia. 2021 Jun;69(6):1478-1493
pubmed: 33556209
Exp Neurol. 2020 Jan;323:113077
pubmed: 31678140
Elife. 2016 Dec 20;5:
pubmed: 27996938
J Neurosci. 2017 Feb 1;37(5):1240-1256
pubmed: 28069922
Adv Sci (Weinh). 2023 Mar;10(8):e2205037
pubmed: 36642841
Aging (Albany NY). 2017 Jun 28;9(6):1607-1622
pubmed: 28657900
J Neurochem. 2006 Aug;98(3):812-23
pubmed: 16893421
J Biol Chem. 2013 Jul 19;288(29):20978-20991
pubmed: 23720741
Front Syst Neurosci. 2016 Oct 26;10:83
pubmed: 27833535
J Neurochem. 1996 Apr;66(4):1641-7
pubmed: 8627321
J Neurosci. 2006 Oct 25;26(43):10939-48
pubmed: 17065436
Crit Care. 2013 May 25;17(3):R94
pubmed: 23706069
J Neurochem. 2015 May;133(4):465-88
pubmed: 25689586
Hippocampus. 2014 Feb;24(2):135-53
pubmed: 24115249
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14500-5
pubmed: 9826729
Neurobiol Dis. 2014 Oct;70:179-89
pubmed: 25008761
Cell Mol Life Sci. 2019 Aug;76(16):3051-3053
pubmed: 31175371
Front Mol Neurosci. 2019 Sep 20;12:220
pubmed: 31616247
Neuron. 2016 May 18;90(4):740-51
pubmed: 27161522
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-81
pubmed: 8446617
J Neurochem. 2010 May;113(3):784-95
pubmed: 20180882
Neurology. 2015 Oct 20;85(16):1383-91
pubmed: 26362286
Alzheimers Dement. 2022 May;18(5):942-954
pubmed: 34482642
Cancers (Basel). 2021 Sep 30;13(19):
pubmed: 34638423
J Alzheimers Dis. 2015;49(4):893-903
pubmed: 26599057
Nat Neurosci. 2014 Dec;17(12):1655-7
pubmed: 25326689
Exp Neurol. 1993 Jun;121(2):149-52
pubmed: 8339766
Hypertension. 2022 Feb;79(2):352-364
pubmed: 34794340
J Neurosci. 2006 Feb 15;26(7):1923-34
pubmed: 16481424
Front Cell Neurosci. 2022 Apr 11;16:838432
pubmed: 35480959
Front Neural Circuits. 2022 Jan 26;15:778022
pubmed: 35177966
Front Neuroanat. 2018 Jan 12;11:137
pubmed: 29375328
Brain Res Bull. 2022 Apr;181:144-156
pubmed: 35066096
Am J Pathol. 2009 Oct;175(4):1586-97
pubmed: 19729478
J Biol Chem. 2006 Aug 25;281(34):24566-74
pubmed: 16787929
Cell Rep. 2019 Nov 19;29(8):2123-2133.e4
pubmed: 31747587
J Alzheimers Dis. 2014;40(2):351-7
pubmed: 24448781
J Neurosci. 2002 Feb 1;22(3):920-30
pubmed: 11826121
Mol Neurodegener. 2021 Nov 22;16(1):78
pubmed: 34809709

Auteurs

Griffin A Greco (GA)

Georgetown University School of Medicine (GUMC), Department of Pharmacology, United States of America.

Mitchell Rock (M)

GUMC, United States of America.

Matthew Amontree (M)

GUMC, United States of America; Interdisciplinary Program in Neuroscience, United States of America.

Maria Fe Lanfranco (MF)

GUMC, Department of Neuroscience, United States of America.

Holly Korthas (H)

Interdisciplinary Program in Neuroscience, United States of America.

Sung Hyeok Hong (SH)

GUMC, Department of Biochemistry and Molecular & Cellular Biology, United States of America.

R Scott Turner (RS)

GUMC, Department of Neurology, United States of America.

G William Rebeck (GW)

Interdisciplinary Program in Neuroscience, United States of America; GUMC, Department of Neuroscience, United States of America.

Katherine Conant (K)

Interdisciplinary Program in Neuroscience, United States of America; GUMC, Department of Neuroscience, United States of America. Electronic address: kec84@georgetown.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH